News
Duke Street Bio News
Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours
First Patient Dosed in Phase I Trial with DSB2455Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the first patient has been dosed in a Phase I trial evaluating the highly...
Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial
Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.
Duke Street Bio Announces Appointment of Chief Medical Officer
Duke Street Bio has strengthed its executive leadership team with the appointment of Dónal Landers, MB BCh BAO, MBA, DPM, FFPM as Chief Medical Officer.
Next Gen PARP1 & PARP7 inhibitor programmes
Duke Street Bio – DDR & IO biotech emerges from stealth mode to discuss its next generation PARP1 and PARP7 inhibitor programmes.
Delivering life-saving cancer treatments to improve patient outcomes.